Understanding the results of the PARAGON‐HF trial
- 25 March 2020
- journal article
- editorial
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (9), 1531-1535
- https://doi.org/10.1002/ejhf.1797
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- Soluble Neprilysin Is Predictive of Cardiovascular Death and Heart Failure Hospitalization in Heart Failure PatientsJournal of the American College of Cardiology, 2015
- Phenomapping for Novel Classification of Heart Failure With Preserved Ejection FractionCirculation, 2015
- Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction TrialCirculation: Heart Failure, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection FractionHeart Failure Clinics, 2014
- Spironolactone for Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJournal of the American College of Cardiology, 2013
- Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection FractionJAMA, 2013
- Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAmerican Heart Journal, 2011
- Pathophysiology of chronic heart failureThe Lancet, 1992